Clinical Trials Directory

Trials / Completed

CompletedNCT05750342

Clinical Trial to Analyze the Efficacy of a Supplement Extracted From Persimmon on Overweight / Obesity.

Randomized Clinical Trial to Analyze the Efficacy of a Supplement Extracted From Persimmon on Overweight / Obesity Grade I in Subjects With Body Mass Index Greater Than 25.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Universidad Católica San Antonio de Murcia · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Randomized, controlled, double-blind clinical trial, with two parallel branches depending on the product consumed (experimental product and placebo product) and single-center, to measure the efficacy of a supplement extracted from Persimmon on overweight and obesity grade I in subjects with BMI over 25.

Detailed description

The product to be consumed is a supplement extracted from the Persimmon. Participants will consume the product for 84 days. They will take one capsule before the two main meals. Subjects will have to make 3 visits to the laboratory. In the initial visit it will be verified if the subject meets the criteria required by the study. Subjects who meet the selection criteria will be randomly assigned to each of the study groups (investigational product or placebo, depending on the group to which they have been assigned). In the other two visits, the subjects will carry out the appropriate tests for taking of data colletion. These visits will be separated by 84 days of product consumption.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTExperimental Product CaquiSupplement extracted from persimmon
DIETARY_SUPPLEMENTControl product placeboProduct with identical characteristics to the experimental product.

Timeline

Start date
2023-02-01
Primary completion
2024-03-28
Completion
2024-05-06
First posted
2023-03-01
Last updated
2024-05-17

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT05750342. Inclusion in this directory is not an endorsement.